RPS11, RPS16, and RPS18 influence the susceptibility of GBM cells to topoisomerase II inhibitor (etoposide) treatment, and a loss of RPS11 leads to resistance to etoposide [147]. The gene discussed is RPS11; the disease is glioblastoma.